ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

In-store opportunities for patients to check in with their health may offer touchpoints to those who don’t regularly seek ...

Access to rehabilitation is a “lifeline” for patients that needs to be protected and preserved to ensure their recovery.

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

The document was designed to promote standardization and identify future research goals in this rapidly-growing field.

Boston Scientific is recommending updates to the instructions for use to minimize the issue, which has been tied to 17 deaths ...

This meta-analysis challenges the randomized FRAIL-AF results, but caution is needed when reconciling the discrepant findings ...

A new meta-analysis lends support to the idea, but researchers caution many specifics must still be worked out.

The law is set to impact hospitals, practices, clinicians, and patients in an already-strained healthcare landscape.

In anthropometric testing, the head of the bed and nursing positions received less scatter with the EggNest versus Rampart.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Some good news, some ‘sobering,’ this month for tricuspid valve interventions, physician payments, and colchicine.